py314
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 29, 2020 (NCT04691375)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma of Lung · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Genital Neoplasms, Female · Phase 1
- Kidney Neoplasms · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Stomach Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1
Mechanism of action
TREM2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04691375 | Phase 1 | Oct 29, 2020 | Gilead Sciences, Pionyr Immunotherapeutics Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 1 | 0 | 1 | 2020 |
| Pionyr Immunotherapeutics Inc. | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1